Zacks Research Equities Analysts Raise Earnings Estimates for Teleflex Incorporated (NYSE:TFX)

Teleflex Incorporated (NYSE:TFXFree Report) – Investment analysts at Zacks Research increased their Q4 2023 earnings estimates for shares of Teleflex in a note issued to investors on Friday, February 9th. Zacks Research analyst R. Anand now forecasts that the medical technology company will post earnings per share of $3.22 for the quarter, up from their previous estimate of $3.21. The consensus estimate for Teleflex’s current full-year earnings is $13.41 per share. Zacks Research also issued estimates for Teleflex’s Q3 2025 earnings at $4.05 EPS and Q4 2025 earnings at $3.98 EPS.

Several other brokerages have also recently commented on TFX. Raymond James raised their price objective on shares of Teleflex from $227.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, December 20th. JMP Securities reduced their price objective on shares of Teleflex from $315.00 to $285.00 and set a “market outperform” rating for the company in a research note on Friday, November 3rd. Royal Bank of Canada raised their price objective on shares of Teleflex from $228.00 to $272.00 and gave the company an “outperform” rating in a research note on Friday, January 12th. Stephens reiterated an “overweight” rating and issued a $275.00 price objective on shares of Teleflex in a research note on Friday, November 3rd. Finally, Morgan Stanley upgraded shares of Teleflex from an “equal weight” rating to an “overweight” rating and set a $261.00 target price for the company in a research report on Monday, December 4th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Teleflex currently has an average rating of “Moderate Buy” and a consensus target price of $269.30.

View Our Latest Research Report on TFX

Teleflex Stock Up 0.3 %

Shares of NYSE TFX opened at $252.73 on Monday. The company has a quick ratio of 2.51, a current ratio of 3.58 and a debt-to-equity ratio of 0.45. Teleflex has a 52 week low of $177.63 and a 52 week high of $276.43. The firm has a 50-day moving average price of $246.20 and a 200 day moving average price of $222.86. The stock has a market capitalization of $11.88 billion, a price-to-earnings ratio of 29.63, a price-to-earnings-growth ratio of 2.29 and a beta of 1.14.

Insider Transactions at Teleflex

In other news, CEO Liam Kelly sold 26,256 shares of Teleflex stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $250.23, for a total transaction of $6,570,038.88. Following the completion of the sale, the chief executive officer now directly owns 18,470 shares in the company, valued at $4,621,748.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Thomas E. Powell sold 13,952 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $222.88, for a total value of $3,109,621.76. Following the completion of the sale, the chief financial officer now directly owns 14,384 shares in the company, valued at $3,205,905.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Liam Kelly sold 26,256 shares of the business’s stock in a transaction that occurred on Wednesday, December 27th. The shares were sold at an average price of $250.23, for a total transaction of $6,570,038.88. Following the completion of the sale, the chief executive officer now owns 18,470 shares of the company’s stock, valued at $4,621,748.10. The disclosure for this sale can be found here. Insiders own 1.41% of the company’s stock.

Institutional Investors Weigh In On Teleflex

Institutional investors have recently bought and sold shares of the stock. Allworth Financial LP grew its holdings in Teleflex by 332.3% in the third quarter. Allworth Financial LP now owns 134 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 103 shares during the period. Lindbrook Capital LLC grew its stake in Teleflex by 75.3% during the fourth quarter. Lindbrook Capital LLC now owns 135 shares of the medical technology company’s stock worth $34,000 after buying an additional 58 shares during the period. Venturi Wealth Management LLC purchased a new stake in Teleflex during the third quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV grew its stake in Teleflex by 418.5% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 140 shares of the medical technology company’s stock worth $35,000 after buying an additional 113 shares during the period. Finally, Covestor Ltd grew its stake in Teleflex by 305.6% during the third quarter. Covestor Ltd now owns 146 shares of the medical technology company’s stock worth $29,000 after buying an additional 110 shares during the period. 97.15% of the stock is currently owned by hedge funds and other institutional investors.

About Teleflex

(Get Free Report)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Read More

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.